Suppr超能文献

相似文献

2
Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
Biochim Biophys Acta. 2009 Sep;1792(9):847-52. doi: 10.1016/j.bbadis.2008.10.008. Epub 2008 Oct 25.
3
Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Curr Osteoporos Rep. 2015 Apr;13(2):78-87. doi: 10.1007/s11914-015-0254-3.
7
Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.
J Invest Dermatol. 2010 Mar;130(3):652-60. doi: 10.1038/jid.2009.337. Epub 2009 Oct 29.
9
Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Calcif Tissue Int. 2021 Jan;108(1):104-115. doi: 10.1007/s00223-020-00659-6. Epub 2020 Jan 22.

引用本文的文献

1
Periarticular Hyperphosphatemic Familial Tumoral Calcinosis in a Saudi Patient: A Case Report.
Cureus. 2025 May 17;17(5):e84292. doi: 10.7759/cureus.84292. eCollection 2025 May.
4
Three Siblings With a Rare Familial Hyperphosphatemia Syndrome: A Case Series.
Cureus. 2024 Mar 5;16(3):e55575. doi: 10.7759/cureus.55575. eCollection 2024 Mar.
5
Recurrent Bilateral Lower Motor Neuron Type of Facial Palsy with Hearing Impairment: Hyperphosphatemic Familial Tumoral Calcinosis.
J Pediatr Genet. 2022 Jan 7;12(4):280-287. doi: 10.1055/s-0041-1741522. eCollection 2023 Dec.
6
PPIGCF: A Protein-Protein Interaction-Based Gene Correlation Filter for Optimal Gene Selection.
Genes (Basel). 2023 May 10;14(5):1063. doi: 10.3390/genes14051063.
7
Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions.
Nat Rev Nephrol. 2023 Mar;19(3):185-193. doi: 10.1038/s41581-022-00665-x. Epub 2023 Jan 9.
8
Phosphate Homeostasis and Disorders of Phosphate Metabolism.
Curr Pediatr Rev. 2024;20(4):412-425. doi: 10.2174/1573396319666221221121350.
9
Hyperphosphatemic familial tumoral calcinosis mimicking a cystic hemo-lymphangioma on MRI.
Radiol Case Rep. 2022 Sep 28;17(12):4603-4607. doi: 10.1016/j.radcr.2022.08.071. eCollection 2022 Dec.

本文引用的文献

2
Hyperphosphatemic tumoral calcinosis: a 10-year follow-up.
J Pediatr Endocrinol Metab. 2011;24(1-2):25-7. doi: 10.1515/jpem.2011.106.
3
Calcitonin administration in X-linked hypophosphatemia.
N Engl J Med. 2011 Apr 28;364(17):1678-80. doi: 10.1056/NEJMc1010928.
4
Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.
J Bone Miner Metab. 2011 Sep;29(5):621-5. doi: 10.1007/s00774-011-0260-1. Epub 2011 Feb 25.
5
Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
Am J Physiol Endocrinol Metab. 2011 Mar;300(3):E508-17. doi: 10.1152/ajpendo.00499.2010. Epub 2010 Dec 7.
6
Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
J Endocrinol. 2010 Oct;207(1):67-75. doi: 10.1677/JOE-10-0181. Epub 2010 Jul 30.
7
Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
Am J Med Genet A. 2010 Apr;152A(4):896-903. doi: 10.1002/ajmg.a.33337.
9
Medical treatment for tumoral calcinosis with eight years of follow-up: a report of four cases.
J Orthop Surg (Hong Kong). 2009 Dec;17(3):379-82. doi: 10.1177/230949900901700328.
10
Tumoral calcinosis.
J Inherit Metab Dis. 2010 Feb;33(1):91-2. doi: 10.1007/s10545-009-9019-4. Epub 2010 Jan 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验